NorstellaLinQ: Identify obesity treatment opportunity before the market does
For GLP-1 therapies, traditional data sources alone aren’t enough to understand the full patient journey. NorstellaLinQ’s 74 billion data points give you the full picture and help you optimize GLP-1 launch strategies in real time. This infographic shows how NorstellaLinQ: Unlocks key information on patients, providers, systems, and payers Uncovers prescribing trends for GLP-1s weeks […]
Inside the Norstella Panel: The engine behind smarter access decisions
The Norstella Panel puts you in the room with the people who decide. Active P&T leaders. Payer and PBM decision makers. Provider and IDN influencers. The voices shaping coverage in real time. As the industry’s leading partner in access, Norstella delivers reach others simply can’t match. Download the infographic to see the scale, specialization, and […]
Norstella’s Real-World Data/AI Executive Forum highlights
The Norstella Real-World Data Executive Forum explores how real-world data (RWD) can accelerate treatment progress in neuro-oncology, particularly for small patient populations and rare subgroups whose outcomes take years to fully measure. Norstella’s mission to “smooth the path to life-saving therapies” guides its RWD strategy, including curating data elements that closely mirror clinical trial inclusion […]
Real-world data, real-world impact
This episode of “Real-World Data After Dark” features Daniel Chancellor, Dr. Madeline Naylor, and Lance Wolkenbrod discussing how integrated real-world data (RWD) is improving patient access to therapies in multiple myeloma. By combining claims, EMR, lab, mortality, and physician note data, Norstella developed clinical profiles that helped identify patients at key disease stages and match […]
Ultimate real-world data showdown
This episode of “Real-World Data After Dark” features Daniel Chancellor, Dr. Madeline Naylor, and Lance discussing how real-world data (RWD), EMR data, and AI are transforming pharma decision-making and patient care. Through a game-show-style conversation, they explore how integrated datasets and unstructured clinical data help generate real-world evidence, improve patient identification, accelerate therapies to market, […]
Real-world data revealed: Getting to know our experts
Real-World Data After Dark is a Norstella mini-series that blends late-night talk show energy with expert conversations on real-world data (RWD) and its importance to the pharmaceutical industry, hosted by Daniel Chancellor, VP of Thought Leadership at Norstella. In this inaugural episode, chief clinician Dr. Madeline Naylor and senior principal of RWD Solutions Lance Wolkenbrod […]
Real-world data in 2025 and beyond: Closing the strategy gap
Real-world data has already proven its power to transform patient outcomes, accelerate clinical development, and strengthen commercial strategies, but its full value is realized only when pharma organizations approach it with a cohesive, forward-looking strategy. Our white paper, Real-world data in 2025 and beyond: Closing the strategy gap, surveyed 200 life sciences executives to gather […]
The ROI of real-world data: Understanding the current and future state of RWD
From clinical trials to regulatory submissions to HEOR research, the value of real-world data (RWD) is clear. So how are today’s pharma leaders using RWD in commercialization strategies, and where are the gaps in realizing its full potential? This infographic reveals the results of Norstella’s survey of 200 life sciences executives about their use of […]
LinQ Cohort: Accelerate feasibility, targeting, and planning
Finding the right patients and HCPs should be fast, but today’s cohorting process slows progress across the lifecycle. This infographic explores how LinQ Cohort, powered by NorstellaLinQ’s linked, tokenized real-world data, helps you: Instantly find and size precise patient populations. Search across structured and unstructured data — EMR, labs, claims, and notes. Explore feasibility, design […]
Working backwards: Patient access strategy is now guiding R&D
Drawing from research from across the breadth of Norstella, this white paper lays out the argument for the increasing strategic influence of patient access. The pricing and reimbursement landscape in the US remains volatile as the various stakeholders react to new policies and the increasing complexity of new drug launches. This is creating the conditions […]